Fuse Oncology is launching its FuseRx prescribing and treatment-intent software for radiation oncology at the American Association of Physicists in Medicine (AAPM) annual meeting in Vancouver, British Columbia.
The platform lets physicians build a structured treatment intent plan -- including simulation orders, prescriptions, and target and organ-at-risk goals -- in a single workflow connecting consult, simulation, planning, and treatment, according to the company. It includes clinic-configurable templates, a validation engine with configurable safety checks, and a change-request audit trail.
FuseRx will integrate the American College of Radiation Oncology's ACROPath pathways directly into its prescribing workflow, building on a strategic agreement between the two organizations announced in March 2025. The product joins Fuse's existing S!GNAL and FuseDocs offerings on a unified platform sharing common patient data and worklist models, the firm said.
